SURAKSHA
1 call
Concalls & earnings callsSuraksha Diagnostic Limited
Every summarised call, newest first. Latest is Q1 FY27, held 13 Aug 2026.
Latest quarter
Q1 FY27 snapshot
Open full brief →Suraksha delivered strong financial performance in Q1 with a 40% PAT growth, successful network expansion, and significant progress in its genomics vertical.
| Metric | This quarter | Change | Five-quarter trend |
|---|---|---|---|
| Total Income | ₹88.7 Cr | 21% | |
| EBITDA | ₹31.5 Cr | 28% | |
| EBITDA Margin | 36% | 2 p.p. | |
| PAT | ₹12.8 Cr | 40% |
Latest guidance
- Overall EBITDA margin for FY27 expected to not go below 34%.
- On track to open 100 centres by FY28.
- Capex for the year expected around Rs. 70-80 crores.
- Expect quarterly growth of around 20-odd percent for the financial year.
Said on the Q1 FY27 call.
Filed results
Reported quarterly history
From filed quarterly results. YoY and QoQ compare each metric on the same accounting basis.
| Quarter | Revenue | Net profit (PAT) | Basic EPS |
|---|---|---|---|
| Q3 FY25 | ₹59.51 Cr— YoY-10.8% QoQ | ₹5.98 Cr— YoY-41.1% QoQ | ₹1.18— YoY-39.2% QoQ |
| Q2 FY25 | ₹66.75 Cr— YoY— QoQ | ₹10.16 Cr— YoY— QoQ | ₹1.94— YoY— QoQ |
Call history
- Q1 FY27Positive tone
Suraksha delivered strong financial performance in Q1 with a 40% PAT growth, successful network expansion, and significant progress in its genomics vertical.
- Total Income
- ₹88.7 Cr21%
- EBITDA
- ₹31.5 Cr28%